Table 3. . Immunotherapy in esophageal, gastric and gastroesophageal junction cancer.
Trial | Subtype adeno/SCC PD-L1+/any | Phase | n | Line of therapy | Intervention | Outcome RR† (%) | Ref. |
---|---|---|---|---|---|---|---|
KEYNOTE-012 Muro et al. |
Adeno | Ib | 39 | >1 | Pembrolizumab | 22 | [99] |
CheckMate 032 Janjigian et al. |
Both | I/II | 160 | ≥2 | Nivo(3) (n = 59) Nivo(1) + ipi(3) (n = 49) Nivo(3) + ipi(1) (n = 52) |
12 24 8 |
[27] |
Kudo et al. | SCC | II | 65 | >2 | Nivolumab | 17 | [100] |
KEYNOTE-059 Fuchs et al. | Adeno | II | 259 25 |
≥3 1 |
Pembrolizumab 3L Pembrolizumab + 5-FU + cisplatin 1l |
11.2 60 |
[24,25] |
ATTRACTION-2 Kang TS et al. |
Adeno | III | 493 | ≥3 | Nivolumab vs placebo | 5.3 vs 4.1 m HR: 0.63 (p < 0.0001) |
[101] |
CheckMate 649 Moehler et al. |
Adeno | III | 1266 | 1 | Nivo/ipi vs nivo vs chemotherapy (oxaliplatin + fluoropyrimidine) | Ongoing | [102] |
CheckMate 649 Janjigian et al. |
Both | III | 870 | 1 | Nivo/ipi vs chemotherapy (oxaliplatin + fluoropyrimidine) | Ongoing | [103] |
KEYNOTE-061 Ohtu et al. | Adeno (HER2+) | III | 720 | 2 | Pembrolizumab vs paclitaxel | Ongoing | [104] |
KEYNOTE-062 Tabernero et al. | Adeno carcinoma (PD-L1+/HER2 -) | III | 750 | 1 | Pembrolizumab vs pembro + cisplatin + 5FU vs placebo + cisplatin + 5-FU | Ongoing | [105] |
†RR except for ATTRACTION-2 (overall survival).
RR: Response rate; SCC: Squamous cell carcinoma.